Consensus Scholar Rock Holding Corporation

Stocks

SRRK

US80706P1030

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2026-11-06 pm EST			5-day change	1st Jan Change
46.94 ^USD	+3.16%		+6.92%	+6.56%

Oct. 28	Scholar Rock Holding Insider Bought Shares Worth $11,999,922, According to a Recent SEC Filing	MT
Oct. 08	Scholar Rock Resubmits Apitegromab Application in EU for Spinal Muscular Atrophy	MT

Evolution of the Average Target: Scholar Rock Holding Corporation

Evolution of the Target Price: Scholar Rock Holding Corporation

Changes in Analyst Recommendations: Scholar Rock Holding Corporation

5f1e296403c1e22d512c14e1e4110.3As8RHovoXVP0fv9gneBCvMlEsI4nBuHiAL6_bQlOSU.sTsEGyBZ1z01uY6s4TnTR4tfR_FO-XTf13GKyf5SahHpWHFyIGXwOjWwug~4809bca3520f07f8eaac7a0ce0df3c9a

Analysts' recommendations: Scholar Rock Holding Corporation

Sep. 25	Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says	MT
Sep. 24	Truist Lifts Price Target on Scholar Rock Holding to $77 From $76, Keeps Buy Rating	MT
Sep. 15	Scholar Rock Shares Fall After Barclays Downgrade	MT
Sep. 15	Barclays Downgrades Scholar Rock to Equalweight From Overweight, Adjusts PT to $58 From $55	MT
Sep. 14	Wedbush Adjusts Price Target on Scholar Rock to $70 From $64, Keeps Outperform Rating	MT
Sep. 14	Truist Raises Price Target on Scholar Rock Holding to $76 From $55, Keeps Buy Rating	MT
Aug. 21	Wedbush Adjusts Scholar Rock Price Target to $64 From $58, Maintains Outperform Rating	MT
Apr. 21	Canaccord Genuity Initiates Scholar Rock at Buy With $62 Price Target	MT
Mar. 31	Wedbush Adjusts Price Target on Scholar Rock Holding to $58 From $56, Maintains Outperform Rating	MT
Mar. 04	Truist Raises Price Target on Scholar Rock Holding to $55 From $44, Keeps Buy Rating	MT
Mar. 03	Wedbush Adjusts Price Target on Scholar Rock to $56 From $50, Maintains Outperform Rating	MT
Jan. 07	UBS Initiates Scholar Rock Holding at Buy With $60 Price Target	MT
Nov. 14	Wedbush Adjusts Pt on Scholar Rock Holding to $50 From $43, Maintains Outperform Rating	MT
25-09-23	HC Wainwright Adjusts Price Target on Scholar Rock Holding to $44 From $50, Maintains Buy Rating	MT
25-09-23	Scholar Rock's Apitegromab Approval Still Likely Despite Delay, Wedbush Says	MT
25-09-17	Barclays Initiates Scholar Rock at Overweight With $45 Price Target	MT
25-09-15	Leerink Partners Initiates Scholar Rock at Outperform With $51 Price Target	MT
25-08-06	Biopharma Scholar Rock Q2 net loss widens, no revenue	RE
25-07-18	Truist Raises Price Target on Scholar Rock Holding to $54 From $45, Keeps Buy Rating	MT
25-07-17	Cantor Fitzgerald Initiates Coverage on Scholar Rock With Overweight Rating	MT
25-02-27	Wedbush Adjusts Scholar Rock Price Target to $50 From $47, Maintains Outperform Rating	MT
24-11-25	Wedbush Raises Price Target on Scholar Rock to $47 From $40, Maintains Outperform Rating	MT
24-11-25	Truist Securities Adjusts Price Target on Scholar Rock to $45 From $36, Maintains Buy Rating	MT
24-11-12	Wedbush Raises Price Target on Scholar Rock to $40 From $37, Maintains Outperform Rating	MT
24-10-08	Scholar Rock's Spinal Muscular Atrophy Drug Plans for Children Under 2 Could Broaden Patient Group, Truist Says	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	SCHOLAR ROCK HOLDING CORPORATION					+50.06%
	WUXI APPTEC CO., LTD.					+37.65%
	ARGENX SE					+23.19%
	LONZA GROUP AG					+7.56%
	BEONE MEDICINES AG					+7.52%
	IQVIA HOLDINGS INC.					+14.74%
	REVOLUTION MEDICINES, INC.					+35.98%
	CELLTRION, INC.					+29.95%
	GENMAB A/S					+13.61%
	INSMED INCORPORATED					+69.73%
	Average					+29.00%
	Weighted average by Cap.					+25.00%